Back to Search Start Over

EVOQ Therapeutics Secures $2 Million in Funding for Advanced Autoimmune NanoDisc Therapies.

Source :
Pharma Business Week; 9/9/2024, p873-873, 1p
Publication Year :
2024

Abstract

The article reports that EVOQ Therapeutics has secured a grant from the National Institutes of Health (NIH) to advance its Nanodisc therapies for autoimmune diseases. Topics include the potential of Nanodisc technology to modulate immune responses in conditions like myelin oligodendrocyte glycoprotein (MOG) antibody disease, the company's ongoing efforts in immunotherapy innovation, and the development of treatments for various autoimmune diseases such as Type One diabetes and Lupus.

Details

Language :
English
ISSN :
15436675
Database :
Complementary Index
Journal :
Pharma Business Week
Publication Type :
Periodical
Accession number :
179480528